Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy.
Joseph MarascioDaniel E SprattJingbin ZhangEdouard J TrabulsiTiffany LeWorlanyo Sosu SedzormeWhitney H BeelerElai DavicioniBashar DabbasDaniel W LinJohn L GoreMatthew BloomMark MannJ Ryan MarkAnne CalvaresiJames L GodwinPeter McCueMark D HurwitzW Kevin KellyCostas D LallasKaren E KnudsenLeonard G GomellaAdam P DickerRobert B DenPublished in: Prostate cancer and prostatic diseases (2019)
The use of GC substantially altered treatment decision-making, with a number needed to test of only 3. Implementing best practices to routinely recommend ART for genomic-high patients led to larger than expected improvements in early biochemical endpoints, without jeopardizing outcomes for genomic-low/intermediate-risk patients.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- healthcare
- decision making
- type diabetes
- primary care
- gene expression
- patient reported outcomes
- metabolic syndrome
- hiv infected
- mass spectrometry
- replacement therapy
- patient reported
- combination therapy
- simultaneous determination
- glycemic control
- benign prostatic hyperplasia